| Drug Name |
Daunorubicin |
| Drug ID |
BADD_D00590 |
| Description |
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. |
| Indications and Usage |
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
Daunorubicin is indicated in combination with [cytarabine] for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.[L32843] |
| Marketing Status |
approved |
| ATC Code |
L01DB02 |
| DrugBank ID |
DB00694
|
| KEGG ID |
D07776
|
| MeSH ID |
D003630
|
| PubChem ID |
30323
|
| TTD Drug ID |
D01XWG
|
| NDC Product Code |
Not Available |
| UNII |
ZS7284E0ZP
|
| Synonyms |
Daunorubicin | Daunomycin | Rubomycin | Dauno-Rubidomycine | Dauno Rubidomycine | Rubidomycin | Daunoblastin | Daunoblastine | NSC-82151 | NSC 82151 | NSC82151 | Cerubidine | Daunorubicin Hydrochloride | Hydrochloride, Daunorubicin |
